(DGAP-Media / 19.08.2014 / 10:21)
Tissue specific optimized AAV Plasmids are now available to make research &
therapy more targeted
Gene Therapy development progresses with tissue specific AAV Plasmids
developed by Europe's leading commercial supplier of viral vectors, SIRION
Biotech in Munich.
Munich, 19 August 2014, viral vectors are a new class of biologics that
help treat diseases caused by defective gene function / proteins ("gene
therapy"). More than 20 companies worldwide the majority of which originate
in the United States are applying viral vectors to conduct clinical
studies.
A key hurdle when applying viral vectors is to limit the transduction (gene
transfer) to the appropriate cells of a specific tissue without affecting
their surrounding environment. But, how can an expression system
differentiate between tissue or even cell type? SIRION Biotech, in
cooperation with U of Munich (LMU) and U of Cologne, has developed a line
of viral vectors with specific promotors that are only active in a specific
set of targetetd cells to initiate the desired gene expression. Using this
method, the gene of interest is only being expressed in the targeted tissue
which is relevant for the desired therapy. This improves the effectiveness
of the therapy and also addresses safety concerns by reducing the
likelihood of side effects.
Recently the company announced a new line of cell specific AAV construction
plasmids, controlling expression in brain & retinal sensory cells, liver,
cardiac and skeletal muscle. They are based on the commonly used AAV 2
single strand serotype and contain a classical multiple-cloning-site (MCS)
for easy, customized manipulation by the experimenter.
SIRION Biotech is offering such plasmids as kits at affordable pricing of $
900 and $ 1.300, making it available to a broad academic and industrial
audience. The packages include the AAV construction plasmids, vector maps
and additional control vectors equipped with an ubiquitous promotor.
About SIRION Biotech www.SIRION-Biotech.com
SIRION Biotech started in Munich in 2007 with the idea of enabling novel
cell models closer to reality than ever before. This required the assembly
of an all-encompassing, novel viral vector platform. Both, designing de
novo viral vectors and the subsequent creation of custom cell models will
pave the way for superior compound development in the life sciences. Many
of SIRION's viral vectors are being used to conducting clinical studies.
SIRION's technologies have been validated in over 400 single projects with
more than 150 academic and industrial partners. As a result, cell models
for drug discovery and development have become highly reliable, as have the
use of new viral vectors in gene therapy and vaccine studies.
Contact SIRION:
SIRION BIOTECH GmbH
Dr. Christian Thirion
Am Klopferspitz 19
D-82152 Martinsried
Tel.: +49-89-700 961 99-15
eMail: Thirion@SIRION-Biotech.com
www.SIRION-Biotech.com
End of Media Release
=--------------------------------------------------------------------
Issuer: Sirion Biotech GmbH
Key word(s): Research/Technology
19.08.2014 Dissemination of a Press Release, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
=--------------------------------------------------------------------
282835 19.08.2014
(END) Dow Jones Newswires
August 19, 2014 04:21 ET (08:21 GMT)
© 2014 Dow Jones News
